Welcome to our dedicated page for CACI INTERNATIONAL /DE/ SEC filings (Ticker: CACI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CACI INTERNATIONAL /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CACI INTERNATIONAL /DE/'s regulatory disclosures and financial reporting.
Director Ryan D. McCarthy of CACI International Inc. exercised 84 Restricted Stock Units on April 14, 2026, converting them into 84 shares of CACI Common Stock at an exercise price of $0.00 per share. After this transaction, he directly owns 2,237 shares of CACI Common Stock and 170 Restricted Stock Units. The exercised RSUs are part of a 338-unit grant awarded on October 17, 2025, scheduled to vest in four installments through October 11, 2026. This filing reflects a routine compensation-related derivative exercise rather than an open-market stock purchase or sale.
CACI International director Scott C. Morrison exercised restricted stock units into common shares as part of a scheduled equity award. On April 14, 2026, 84 RSUs converted into 84 shares of CACI Common Stock at a stated price of $0.00 per share, increasing his direct holdings to 499 shares. A prior grant of 338 RSUs made on October 17, 2025 is scheduled to vest in four tranches: 84 shares on January 14, 2026, 84 shares on April 14, 2026, 85 shares on July 13, 2026, and 85 shares on October 11, 2026.
CACI International director Philip O. Nolan exercised restricted stock units into common shares as part of his equity compensation. On April 14, 2026, 84 RSUs converted into 84 shares of CACI common stock at a stated price of $0.00 per share, a non-cash equity award.
Following the transaction, Nolan directly held 2,237 CACI common shares and 170 restricted stock units. The footnote explains these RSUs come from a grant of 338 RSUs on October 17, 2025, vesting in four scheduled tranches through October 2026, indicating this is a routine, pre-set vesting event rather than an open-market trade.
CACI International director Lisa S. Disbrow exercised 123 Restricted Stock Units into 123 shares of CACI common stock on April 14, 2026. This transaction increased her direct common share holdings to 2,277 shares and left 246 Restricted Stock Units outstanding from a 492-unit grant awarded on October 16, 2025.
CACI International director Debora A. Plunkett exercised 84 Restricted Stock Units into 84 shares of CACI common stock at a stated price of $0.00 per share. The RSUs are part of a 338-unit grant awarded on October 17, 2025 with scheduled vesting dates through October 11, 2026. Following this transaction, she holds 2,512 shares of CACI common stock directly and 170 RSUs that remain unvested from the same grant.
CACI International director Charles L. Szews reported an exercise of 84 Restricted Stock Units into CACI common stock. The transaction occurred on April 14, 2026 and increased his directly held common shares to 499.
The 84 RSUs exercised are part of a 338-unit grant awarded on October 17, 2025, vesting in four tranches: 84 shares on January 14, 2026, 84 on April 14, 2026, 85 on July 13, 2026, and 85 on October 11, 2026. This filing reflects a routine compensation-related vesting and share delivery, with no open-market buying or selling.
CACI International director Stanton D. Sloane exercised restricted stock units into common shares as part of a vesting schedule. On April 14, 2026, 84 Restricted Stock Units converted into 84 shares of CACI common stock at an exercise price of $0.00 per share, increasing his direct holdings to 1,027 common shares.
These RSUs come from a grant of 338 units awarded on October 17, 2025, which vests in four installments through October 2026. The transaction reflects routine, compensation-related equity vesting rather than an open-market purchase or sale.
CACI International Inc: The Vanguard Group filed an amendment on its Schedule 13G/A reporting that, after an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report beneficial ownership separately and The Vanguard Group reports 0 shares and 0% beneficial ownership of CACI common stock.
The filing explains the change follows SEC Release No. 34-39538 and states the disaggregated subsidiaries pursue the same investment strategies previously used by Vanguard. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
CACI International Inc completed a debt financing by issuing $500 million of additional unsecured 6.375% Senior Notes due 2033 as part of its existing notes series. After this offering, total senior notes outstanding in this series are $1.5 billion.
CACI sold the additional notes in a private placement to initial purchasers and received net proceeds of approximately $518 million. The company plans to use these proceeds to repay borrowings under its revolving credit facility that were used to help fund the ARKA Group L.P. acquisition and related costs.
Director Debora A. Plunkett reported an open-market sale of 220 shares of CACI Common Stock on March 11, 2026 at an average price of $603.30 per share. After this transaction, she directly holds 2,428 shares of CACI common stock.